Abstract
We have presented evidence for a strong nonrandom association between the ability to mount an IgE immune response and the development of bronchial asthma. Failure to address the issue of allergen-induced asthma is likely to result in inadequate control of the condition, higher morbidity, and unfortunately, increased costs to the patient and society than would otherwise be necessary. With thorough allergic assessment, the clinician will always be in a better position to invoke specific avoidance measures, select the best pharmacotherapy for the patient, and be in the best position to judge the need for immunotherapy. The latter decision should be dependent on allergic triggers that play a principal role in the asthmatic condition, the availability of a standardized extract, and evidence that environmental control and simple pharmacotherapy are inadequate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
